术前中性粒细胞与淋巴细胞比值对淋巴结转移的胸段食管鳞癌病人预后的预测价值

目的探讨术前中性粒细胞与淋巴细胞比值(NLR)对淋巴结转移的胸段食管鳞癌病人预后的预测价值。方法 2014年4月～2016年4月我院行手术治疗的胸段食管鳞癌病人313例,以病人NLR中位值3.2为界值,将所有病人分为高NLR值(≥3.2)组和低NLR值(3.2)组。比较两组的一般临床病理特征,绘制两组的总生存期(OS)与无病生存期(DFS)生存曲线并进行比较。使用Cox比例风险模型进行多因素分析以确定预后相关的因素。结果高NLR组与低NLR组病人的1年、3年OS率分别为86.5%、56.2%和88.9%、61.0%(P0.05),高NLR组与低NLR组病人的1年、3年DFS率分别为71.1%、35.3%和83.1%、47.1%(P0.05)。多因素分析显示,病理分期是OS的独立预后因素(P0.05),而手术入路、肿瘤分化程度、病理分期及NLR是DFS的独立预后因素(P0.05)。结论对于已存在淋巴结转移的食管胸段鳞癌病人, NLR值对于病人复发预测具有价值,但是对于其总生存期来说,并不能作为预测指标。     

P-糖蛋白(Pgp)在乳腺癌中的表达及与预后的关系

目的探讨P-糖蛋白(P-glycoprotein,Pgp)在乳腺癌中的表达,评估其在乳腺癌预后中的作用。方法对我院1993年1月～1994年12月用免疫组织化学方法检测62例手术切除的乳腺癌组织中Pgp的表达的资料进行回顾分析,研究其与临床病理特征的关系及对预后的影响。结果(1)Pgp在乳腺癌组织中的阳性表达率为32.2%(20/62)。(2)Pgp表达与月经状况、肿瘤大小、腋淋巴结转移个数、组织学分级之间均无相关性(P>0.05)。(3)Kaplan-Meier生存分析结果表明Pgp阴性表达组的无病生存期(DFS)及总生存期(OS)均明显优于阳性表达组(P<0.05)。(4)Cox回归单因素分析显示腋窝淋巴结转移个数、组织学分级、肿瘤大小、TNM分期及Pgp表达与DFS及OS明显相关;Cox回归多因素分析表明除了腋窝淋巴结转移个数、组织学分级及肿瘤大小与DFS及OS明显相关外,Pgp表达与OS缩短有关,但和DFS无关。结论Pgp在乳腺癌组织中有一定程度的表达,Pgp阳性表达与乳腺癌患者生存期的缩短有关,有可能成为判断乳腺癌患者预后的指标。     

淋巴细胞与单核细胞比值在肝细胞癌患者中的预后价值分析

背景与目的:通过实验室血样进行评估系统性炎症的临床意义已在多种癌症中被证实。肝细胞癌(HCC)是一种炎症驱动型癌症,炎症已被证实与分化不良、微血管侵犯和微转移相关。本研究旨在探讨淋巴细胞/单核细胞比值(LMR)对HCC患者术后的预后评估价值。方法:回顾性分析2012年1月—2016年12月在南京中医药大学附属南京医院行根治性肝切除术的88例HCC患者的资料。通过ROC曲线分析LMR评估HCC预后的性能,并将其与中性粒细胞/淋巴细胞比值(NLR)和血小板/淋巴细胞比值(PLR)进行比较。分析LMR与HCC患者临床病理因素的关系,以及与无病生存率(DFS)、总生存率(OS)的关系。用Cox回归模型分析DFS和OS的危险因素。结果:ROC曲线确定LMR最佳诊断界值为2.87,曲线下面积(AUC)为0.757,其评估HCC预后的性能大于NLR(AUC=0.687)和PLR(AUC=0.583)。根据LMR界值将患者分为高LMR组(LMR2.87)与低LMR组(LMR≤2.87)。高LMR组中肿瘤数3的例数明显少于低LMR组(P=0.048);高LMR组的DFS与OS均明显优于低LMR组(均P0.05);在分期分层(BCLCA/B、BCLCC/D;CNLCⅠ/Ⅱ、CNLCⅢ/Ⅳ)比较结果显示,除了在CNLCⅠ/Ⅱ期组患者中,高LMR组与低LMR组的DFS无统计学差异(P=0.132),在其他分期组患者中,高LMR组患者的DFS与OS均明显优于低LMR组(均P0.05)。LMR为DFS的独立影响因素(P=0.001),而BCLC分期(P=0.000)和LMR(P=0.000)为OS的独立影响因素,此外,对LMR、PLR与NLR以连续性变量形式进行校正后,仅LMR具有预后价值(P=0.001)。结论:LMR是HCC患者术后DFS和OS的独立预后因素,且评估价值可能优于NLR和PLR。用LMR结合HCC分期对患者进行危险分级,可能做出更为精准的评估。     

保留乳头乳晕复合体的乳腺癌改良根治术预后的相关因素分析

目的探究影响保留乳头乳晕复合体(NAC)的乳腺癌改良根治术(NSM)预后的相关因素。 方法回顾性分析2011年1月至2014年12月84例早期原发性乳腺癌并接受NAC的NSM患者临床病理资料。使用统计软件SPSS 20.0进行数据分析,采用K-M生存曲线评估术后无病生存(DFS)及总生存(OS),采用单因素分析和Cox多因素分析影响NSM术后患者DFS和OPS的影响因素。P<0.05差异有统计学意义。 结果术后局部复发8例,远处转移6例,术后5年DFS为83.3%,OS为91.7%。多因素分析显示,肿瘤最大径、肿瘤距乳头乳晕距离(TND)、腋窝淋巴结状态、组织学类型及Her-2阳性是影响DFS的独立危险因素(P<0.05);而腋窝淋巴结状态是影响术后OS的独立危险因素(P<0.05)。 结论肿瘤最大径、TND、腋窝淋巴结状态、组织学类型及Her-2阳性是DFS的独立危险因素,腋窝淋巴结状态是OS的独立危险因素;腋窝淋巴结情况同时影响患者术后DFS和OS,术前系统、精准地评估并妥善处理特殊腋窝淋巴结可提高乳腺癌患者预后。     

术前外周血白细胞相关炎性指标预测结肠癌预后价值分析

目的 分析术前外周血白细胞相关炎性指标对非转移性结肠癌病人预后的预测价值。方法 回顾性分析2016年1月至2017年9月北京协和医院基本外科结直肠专业组收治的554例行结肠癌根治术病人的临床病理资料。Kaplan-Meier法分析白细胞（WBC）计数、中性粒细胞百分比（NE%）和中性粒细胞与淋巴细胞比值（NLR）与病人生存预后的关系;通过多因素COX回归分析影响病人预后的因素。结果 WBC、NLR和NE%的最佳截断值分别为8.25×109/L、2.27和59.0%。单因素分析显示,病人术前癌胚抗原（CEA）、NE%和NLR值和术后病理N分期与总生存（OS）、无病生存（DFS）均有相关性;病人年龄、术前WBC仅与OS具有相关性。多因素分析显示,病人术后病理N分期（HR=2.634,95%CI 1.441～4.814,P=0.002）和NLR（HR=1.098,95%CI 1.028～1.173,P=0.005）是OS的独立危险因素;术后病理N分期（HR=2.512,95%CI 1.627～3.880,P<0.001）和NLR（HR=1.101,95%CI 1.037～1.169,P=0.002）是DFS的独立危险因素;病人年龄≥65岁是OS（HR=1.042,95%CI 1.013～1.072,P=0.005）的独立危险因素。结论 虽然术前外周血NLR升高的非转移性结肠癌病人预后较差,但NLR值对病人预后ROC曲线区分度较低,故不建议将术前外周血白细胞相关炎性指标作为非转移性结肠癌预后的标记物。     

70岁以上女性乳腺癌临床病理特征及预后分析

目的:分析70岁以上女性乳腺癌患者的临床病理特征、治疗方式及预后影响因素。方法:回顾2007年1月—2010年12月哈尔滨医科大学附属肿瘤医院乳腺外科接诊并接受手术治疗的203例70岁以上老年女性乳腺癌患者的临床资料,分析其临床病理特点及生存情况。结果:203例患者中,临床TNMⅠ期患者67例(33.0%),Ⅱ期患者117例(57.6%);无腋窝淋巴结转移患者92例(53.5%);浸润性导管癌166例(81.8%),为主要病理类型;177例行免疫组织化学检查,ER、PR阳性与HER-2过表达患者分别为123例(69.5%)、114例(64.4%)、23例(13.0%);乳腺癌改良根治术153例(75.4%),为主要手术方式;术后接受内分泌治疗患者111例(54.7%),化疗患者28例(13.8%)。单因素分析显示年龄、淋巴结状态、ER、PR、组织学分级与内分泌治疗与患者总生存时间(OS)有关,淋巴结状态、ER、PR、HER-2、内分泌治疗与化疗与患者无病生存时间(DFS)有关(均P0.05);COX多因素分析显示年龄、淋巴结状态和PR为OS的独立影响因素,淋巴结状态为DFS的独立影响因素(均P0.05)。结论:老年女性乳腺癌具有独特生物学特性,主要治疗方式为手术治疗。年龄、淋巴结状态和PR是老年女性乳腺癌的独立预后因素。     

细胞核内β-连环素表达水平在胃癌中的临床研究

目的:探讨细胞核内β-连环素表达水平与胃癌临床病理因素的关系。方法:应用免疫组织化学SP法检测77例胃癌组织及30例癌旁组织细胞核中β-连环素表达水平,分析其与肿瘤组织浸润深度、淋巴结转移、组织分化程度、临床分期的关系。以无病生存时间(DFS)和总生存时间(OS)为评价指标,探讨β-连环素与胃癌患者预后的关系;ROC曲线衡量β-连环素在评估胃癌患者预后中的价值。结果:胃癌肿瘤组织细胞核内β-连环素的表达水平与年龄、性别无关(P0.05),与肿瘤的浸润深度、淋巴结的转移、TNM分期以及肿瘤的分化程度有关。Kaplan-Meier生存曲线显示:肿瘤组织细胞核内β-连环素阴性表达者DFS(26月)和OS(38月)优于阳性表达者DFS(18月)和OS(24月)(P0.05);COX多因素分析:细胞核内β-连环素的表达可以作为胃癌患者OS独立预后因素(HR=0.87,95%CI:0.54~2.34,P=0.03);ROC曲线显示,β-连环素在评估胃癌患者预后中具有中等价值(曲线下面积为0.82)。结论:胃癌组织细胞核内β-连环素表达水平与胃癌的TNM分期、淋巴结转移、浸润深度呈正相关性,与肿瘤的分化程度呈负相关性,可能是胃癌患者预后较差的标志物。     

混合型肝癌预后评价及相关影响因素分析

目的 评价混合型肝癌（cHCC-CC）病人的预后并分析与预后相关的影响因素。方法 回顾性分析2015年9月至2019年9月海军军医大学东方肝胆外科医院收治的54例cHCC-CC病人的临床资料。随访观察3年,采用Kaplan-Meier法进行生存分析,并分析cHCC-CC病人预后的影响因素。结果 54例cHCC-CC病人术后1、2、3年总体生存率为84.7%、61.1%、47.0%,无病生存率为50.8%、46.9%、26.4%,中位生存期（OS）、无病生存期（DFS）分别为29.1、17.7个月。单因素分析显示,肿瘤最大径≥5 cm、微血管侵犯、淋巴结转移为OS和DFS的影响因素。Cox多因素分析显示,肿瘤最大径≥5 cm（P=0.035）、微血管侵犯（P=0.023）、淋巴结转移（P=0.041）为OS的独立危险因素;微血管侵犯（P=0.007）、淋巴结转移（P=0.024）是DFS的独立危险因素。结论 cHCC-CC预后较差,兼有肝细胞癌及胆管细胞癌的特点,肿瘤直径≥5 cm、微血管侵犯及淋巴结转移影响病人预后生存,建议据此选择个体化治疗方案。     

血清HBeAg状态对肝细胞癌患者术后生存的影响

目的研究肝癌患者血清HBeAg状态对肝癌切除术后复发及生存的影响。方法收集1999~2005年在我科行根治性切除的223例肿瘤直径≤3cm的肝癌患者的资料。根据患者术前血清HBeAg状态,分为HBeAg阳性组(n=73)和HBeAg阴性组(n=150),比较2组患者无瘤生存率(DFS)和总体生存率(OS),并分析影响DFS和OS的危险因素。结果HBeAg阳性和HBeAg阴性患者的1、3、5年的OS分别为91.5%、76.8%、60.1%和95.2%、85.3%、73.2%(P=0.053);1、3、5年DFS分别为73.3%、53.7%、40.3%和86.6%、65.5%、54.5%(P=0.002)。与HBeAg阴性组比较,HBeAg阳性组患者年龄较轻(P=0.004),肝硬变较重(P=0.008),而在肿瘤因素及手术相关因素方面2组间的差异无统计学意义(P>0.05)。对DFS和OS的多因素分析显示,年龄>50岁、HBeAg阳性和大结节肝硬变是影响OS的独立危险因素,而HBeAg阳性和多发肿瘤是影响DFS的独立危险因素。结论小肝癌患者术后HBeAg阳性患者较HBeAg阴性者更易早期复发,而且总体生存较差。     

术前中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对肾透明细胞癌的预后评估价值

目的:探究术前外周血中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)在评估肾透明细胞癌(ccRCC)患者预后的作用。方法:回顾性分析2001年12月—2010年12月在我院接受手术治疗的352例肾细胞癌(RCC)患者的临床资料,年龄25~82岁,平均(55.1±12.2)岁;随访时间1~200个月,平均(106.1±35.1)个月;中位总生存期(OS)为104个月,中位无复发生存期(RFS)为101个月。通过受试者工作特征曲线(ROC)确定NLR及PLR的最佳临界值并进行分组,通过Kaplan-Meier法和Cox回归对RCC患者中的NLR及PLR进行预后分析。结果:按最佳临界值NLR<2.05(155例)及≥2.05(197例)、PLR<140(236例)及PLR≥140(116例)对患者进行分组。高NLR及PLR与大肿瘤直径(P=0.026,P=0.019)、高肿瘤TNM分期(P=0.003,P<0.001)、高肿瘤Fuhrman分级(P=0.021,P=0.008)及转移或复发有关(P<0.001,P<0.001)。相比于单独使用NLR或PLR,联合NLR及PLR能够更有效地预测OS及RFS。Cox多因素分析结果提示高NLR(P<0.001)、高PLR(P=0.004)、患者年龄≥60岁(P<0.001)、大肿瘤直径(P=0.043)、高肿瘤TNM分期(P<0.001)、高肿瘤Fuhrman分级(P<0.001)与患者OS相关,并且高NLR(P=0.012)、高PLR(P=0.014)、高肿瘤TNM分期(P<0.001)、高肿瘤Fuhrman分级(P=0.002)与患者RFS相关。结论:术前NLR及PLR是ccRCC患者术后OS及RFS的独立预后因素。高NLR、PLR预示着ccRCC患者较高的复发转移风险及较差的生存预后。     

术前中性粒细胞与淋巴细胞比值对胰腺癌手术患者预后价值的Meta分析

背景与目的：胰腺癌是恶性程度极高的实体恶性肿瘤之一,因早期缺乏症状导致多数患者确诊时已处于局部进展期或晚期。因此,探索术前判断预后的标志物对临床制定诊疗策略至关重要。目前,术前中性粒细胞与淋巴细胞比率（NLR）与胰腺癌患者预后的关系尚存在争议。本研究使用Meta分析方法,探讨术前NLR与胰腺癌患者术后生存获益之间的关系及其预后价值。方法：计算机检索PubMed、Cochrane Library、Web of Science、中国知网、维普及万方数据库收集术前NLR值与胰腺癌患者术后总体生存期（OS）和无病生存期（DFS）关系的研究,检索时限均从建库至2022年3月31日,由两名评价员独立筛选并纳入文献,提取资料并评价纳入研究的偏倚风险后,利用Revman 5.4和Stata 16.0软件对风险比（HR）和95%可信区间（CI）进行合并,并根据异质性选择对应的效应模型。对纳入研究的文献进行敏感度分析,用Egger回归检验判断纳入文献是否存在显著发表偏倚。结果：共纳入25项回顾性研究,4 796例研究对象。研究中有24篇文献报道了NLR与术后OS之间的关系,6篇报道了NLR与术后DFS之间...     

Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer

Aim Current management of locally advanced rectal cancer includes neoadjuvant chemoradiation in selected patients to increase the chance of a tumour‐free circumferential resection margin. There is uncertainty over the role of and selection criteria for additional systemic therapy in this group of patients. In this retrospective study we investigate the association between markers of systemic inflammatory response (SIR) and outcome from treatment. Method One hundred and fifteen patients with locally advanced rectal cancer undergoing preoperative chemoradiation had recording of full blood count parameters including neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratios (PLR). Postoperative surgical margins (R status) and pathological stage were documented. Outcome measures were overall survival (OS), time to local recurrence (TTLR) and disease‐free survival (DFS). Cox regression analysis was performed to identify predictors of outcome. Results Only NLR and R status were significant predictors for all outcome measures on univariate and multivariate analysis. Elevated NLR (≥ 5) was associated with decreased OS, [hazard ratio (HR) and 95% CI, 7.0 (2.6–19.2)], decreased TTLR [HR 3.8 (1.3–11.2)] and shorter DFS [HR 4.1 (1.7–9.8)]. Median survival for patients with an elevated NLR was 18.8 months compared with 54.4 months without an elevated NLR (P < 0.001). Conclusion In addition to postoperative R‐status, an elevated NLR is also a valuable prognostic marker in patients undergoing chemoradiation for locally advanced rectal carcinoma. It is associated with worse OS, TTLR and DFS. An elevated NLR may be a useful additional tool in guiding the decision‐making process for adjuvant or neoadjuvant therapies.     

The Usefulness of the Pretreatment Neutrophil/Lymphocyte Ratio as a Predictor of the 5-Year Survival in Stage 1–3 Triple Negative Breast Cancer Patients

BackgroundWe have previously shown that the neutrophil/lymphocyte ratio (NLR) is a predictor of survival among breast cancer patients. The aim of this study was to determine the predictive value of NLR among different nodal and chemotherapy subgroups of triple negative breast cancer (TNBC).MethodsPatients with stage 1–3 TNBC who underwent treatment from 2007 to 2014 and had blood counts prior to treatments were included. Patients were categorized into high (≥2) and low (<2) NLR groups. Primary outcomes were overall survival (OS) and disease-free survival (DFS).ResultsThe average follow-up time was 54 months. The high NLR group had worse OS (HR 2.8, CI 1.3–5.9, p < 0.001) and DFS (HR 2.3, CI 1.2–4.2, p < 0.001) than the low NLR group. After adjusting for confounding variables, high NLR was an independent prognostic factor for both OS (HR 5.5, CI 2.2–13.7, p < 0.0001) and DFS (HR 5.2, CI 2.3–11.6, p < 0.0001). Categorization of TNBC patients by NLR (high vs. low) and nodal status (positive vs. negative) resulted in four groups with significantly different OS and DFS (log rank p < 0.0001). Significant improvements in OS (p < 0.001) and DFS (p < 0.001) were observed for patients who received chemotherapy and had high NLR but not for patients with low NLR (p = 0.65 and p = 0.07, respectively).ConclusionHigh pretreatment NLR is an independent predictor of poor OS and DFS among TNBC patients. Combining NLR and pN provides better risk stratification for TNBC patients. Chemotherapy appears to be beneficial only in patients with high NLR. Larger prospective studies are needed to validate these findings.     

Association with pregnancy increases the risk of local recurrence but does not impact overall survival in breast cancer: A case–control study of 87 cases

Pregnancy-associated breast cancer (PABC) constitutes 7% of all BCs in young women. The prognosis of PABC remains controversial. In this study, we evaluated the impact of the association of pregnancy with BC on the rates of overall survival (OS), disease free survival (DFS), and distant and local recurrence-free survival.We conducted a retrospective unicenter case–control study. We enrolled PABC patients treated at our institution between 1992 and 2009. For each case, 2 BC controls were matched for age and year of diagnosis. Univariate and multivariate analyses were performed to assess the parameters associated with prognosis.Eighty-seven PABC patients were enrolled and matched with 174 controls. The univariate analysis did not reveal any significant differences in OS, DFS or distant recurrence rates between the 2 groups. Pregnancy associated status, a tumor larger than T2 and neoadjuvant chemotherapy as the primary treatment were significantly associated with an increased risk of local relapse. The multivariate analysis showed that the pregnancy associated status and the tumor size were strong prognostic factors of local recurrence. Pregnancy associated status negates the prognostic value of tumor size, as both T0–T2 and T3–T4 PABC patients have the same poor prognosis as control BC patients with T3–T4 tumors. Interestingly, although PABC patients have more locally advanced tumors, they did not have a higher rate of radical surgery than the control BC patients.Pregnancy associated status is a strong prognostic factor of local relapse in BC. In PABC patients, when possible, radical surgery should be the preferred first treatment step.     

Survival outcomes in pregnancy associated breast cancer: a retrospective case control study

Pregnancy-associated breast cancer (PABC) has been defined as breast cancer diagnosed during pregnancy or within one year of delivery. It is believed that after adjusting for age and stage, the 5-year survival rates are the same in both pregnant and nonpregnant women. We conducted a retrospective case-control study among patients treated at our institution between 1990 and 2005 to compare the 5-year survival outcomes for PABC with women treated for breast cancer who were not pregnant. Overall survival (OS) and disease-free survival (DFS) were estimated by the Kaplan-Meier method, and log rank tests were used to assess the associations between OS, DFS and pregnancy status, HER-2 status, ER/PR status, and family history. The median age was 33 years (range 24-42) for both groups. Twenty-two (55%) patients with PABC were ER/PR receptor positive compared with 20 (50%) for the controls. Ninety percent of patients with PABC received chemotherapy compared with 87.5% in the nonpregnant group. 91.5% of patients with PABC had breast-conserving surgery and 8.5% had mastectomies compared with 86% and 14%, respectively, for the control group. The median OS was 4.9 years in the PABC group compared with 6 years for the controls (p = 0.02). The median DFS was 2.7 years for the PABC group compared with 5.1 years for the controls (p = 0.01). The most common site of relapse was bone for the PABC group (27%) and local recurrence (33%) for the controls. Univariate analysis revealed that OS and DFS were associated with pregnancy status, family history, ER/PR status, and stage. After adjusting for age and stage, PABC patients had higher risk of both death (p = 0.01) and recurrence (p = 0.02) compared with nonpregnant controls. Women with PABC had significantly shorter OS and DFS compared with nonpregnant age and stage-matched controls.     

胃癌组织中p-mTOR表达与患者预后的关系

目的探讨中国人胃癌组织中哺乳动物雷帕霉素靶蛋白（mTOR）的活化形式p—mTOR蛋白的表达与胃癌预后的关系。方法采用免疫组化方法检测181例胃癌组织中P—mTOR蛋白的表达情况,分析其与胃癌预后的关系。单因素分析采用Kaplan—Meier法计算患者存活率并比较平均生存时间,多因素分析用COX回归模型。结果181例胃癌标本中p—mTOR蛋白表达阳性93例,阳性表达率为51．4％。与p—mTOR表达阴性患者比较,其阳性患者的患者总存活率与无病存活率明显缩短（组间比较DFS,P〈0．01;OS,P〈0．05）。多因素分析结果显示,p-mTOR的表达与预后呈负相关。结论胃癌组织中p—mTOR蛋白的表达是影响胃癌预后的因素之一。     

术前外周血中性粒细胞／淋巴细胞比值在结直肠癌预后评估中的价值

目的探讨术前外周血中性粒细胞／淋巴细胞比值（NLR）对结直肠癌患者预后评估的价值。方法回顾性分析2005年7月至2011年7月问在解放军总医院普通外科接受根治性手术且术后随访资料完整的140例结直肠癌患者的临床资料。根据患者术前外周血NLR分为低NLR组（小于5,105例）和高NLR组（大于或等于5,35例）,比较两组患者的术后5年生存率并进行预后分析。结果低NLR组和高NLR组结直肠癌患者术后5年生存率分别为74-8％和54．7％,差异有统计学意义（P=0．03）。单因素分析显示,术前NLR、肿瘤位置、浸润深度、淋巴结转移及肿瘤分期与本组患者术后生存有关（P〈0．05和P〈0．01）;多凶素预后分析证实,NLR是影响本组结直肠癌患者预后的独立危险因素（RR=I．068,95％c1：1．009～1．129,P=0．02）。结论术前NLR大于或等于5提示结直肠癌患者预后较差。     

Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China

BACKGROUND: The purpose of this study was to investigate the clinicopathological features and analyze the prognostic factors of triple-negative breast cancer (TNBC). PATIENTS AND METHODS: The clinical data of 1,788 breast cancer patients was collected and analyzed. The Kaplan-Meier method was used to estimate survival. Multivariate analysis of the prognostic factors for survival was performed using the Cox regression model. RESULTS: Patients with TNBC exhibited characteristics significantly differing from those with non-TNBC. There was a higher proportion of patients with age < 35 years, stage III disease, tumor size > 5 cm, lymph node positivity, and histological grade 3. The 5-year disease-free survival (DFS) rates of TNBC and non-TNBC patients were 75.7 and 79.6%, respectively (p < 0.05). 5-year overall survival (OS) was 86.6 and 93.5%, respectively (p < 0.05). In multivariate Cox regression analysis, the independent prognostic factors for shorter DFS were age < 35 years (hazard ratio (HR) 2.105), positive lymph nodes (HR 7.039), histological grade 3 (HR 1.841), and for shorter OS positive lymph nodes (HR 4.626). CONCLUSION: The proportion of TNBC in breast cancer in China is higher than in other areas. TNBC is correlated with younger age, larger tumor size, positive lymph nodes, higher clinical stage and histological grade, and lower DFS and OS, which is consistent with previous reports.